Clinical Studies – Targeting Acute and Chronic Thromboembolic Disorders
____________

First Published, Prospective, International, Observational Study of a NOAC for the Treatment and Secondary Prevention of VTE

 

XALIA:
First Published, Prospective, International, Observational Study with a NOAC (Xarelto®) in DVT


Objective

  • Collect Real-World data in patients with acute DVT treated with Xarelto or standard anticoagulation therapy*
     

Study Design

  • A large, multicentre, prospective, non-interventional study to evaluate the safety and efficacy of Xarelto in the Real World
  • Patients were enrolled from June 2012 to March 2014 from 19 countries in Europe, plus Canada and Israel
     

Population

5,142 adults with acute DVT and an indication to receive anticoagulation therapy for at least 3 months, who were treated with Xarelto or standard anticoagulation therapy*
 

Key patient characteristics of Xarelto patients are consistent with EINSTEIN DVT

Xalia key patient characteristics
Xalia key patient characteristics

CrCl, creatinine clearance; DVT, deep vein thrombosis; VTE, venous thromboembolism. * Initial treatment with unfractionated heparin, low-molecular-weight heparin or fondaparinux; usually overlapping with and followed by a vitamin K antagonist.

 

PP-XAR-ALL-1819-1


    • 1
      Ageno W, et al. Lancet Haematol. 2016;3(1):e12–e21.
    • 2
      Bauersachs R, et al. N Engl J Med. 2010;363:2499–2510.

    • a
      Deep vein thrombosis (= DVT). A blood clot in a deep vein, usually resulting from damage to the vein or blood flow slowing down or stopping. Usually DVTs are found in the leg, but can also be in the arm. Distal DVTs are found in deep veins of the calf, and are the most common type of DVT. Proximal…
    • b
      Formation of a clot inside a blood vessel.
    • c
      Venous thromboembolism (= VTE). A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.